Cullinan Therapeutics Future Growth

Future criteria checks 2/6

Cullinan Therapeutics's earnings are forecast to decline at 9.3% per annum while its annual revenue is expected to grow at 62.9% per year. EPS is expected to grow by 1.9% per annum. Return on equity is forecast to be -42.7% in 3 years.

Key information

-9.3%

Earnings growth rate

1.9%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	62.9%
Future return on equity	-42.7%
Analyst coverage	Good
Last updated	19 Nov 2024

Recent future growth updates

Recent updates

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGS:CGEM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	27	-204	N/A	-174	10
12/31/2025	7	-198	N/A	-164	9
12/31/2024	N/A	-167	N/A	-111	8
9/30/2024	N/A	-144	-127	-127	N/A
6/30/2024	N/A	-142	-127	-127	N/A
3/31/2024	N/A	-132	-122	-122	N/A
12/31/2023	N/A	-153	-134	-134	N/A
9/30/2023	N/A	-156	-142	-141	N/A
6/30/2023	N/A	-142	-163	-161	N/A
3/31/2023	N/A	65	-157	-156	N/A
12/31/2022	N/A	111	-128	-127	N/A
9/30/2022	N/A	105	-117	-117	N/A
6/30/2022	N/A	113	-73	-73	N/A
3/31/2022	N/A	-78	-64	-64	N/A
12/31/2021	19	-66	-43	-43	N/A
9/30/2021	19	-61	-38	-38	N/A
6/30/2021	19	-54	-36	-36	N/A
3/31/2021	19	-47	-26	-26	N/A
12/31/2020	N/A	-52	-30	-30	N/A
9/30/2020	N/A	-28	-25	-25	N/A
6/30/2020	N/A	-25	-22	-22	N/A
3/31/2020	N/A	-21	-21	-21	N/A
12/31/2019	N/A	-21	-21	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEM's revenue (62.9% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CGEM's revenue (62.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CGEM is forecast to be unprofitable in 3 years.

Cullinan Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$3.01 loss

Consensus revenue estimates increase by 19%

Price target increased by 13% to US$28.71

Price target decreased by 11% to US$25.25

Price target decreased to US$34.00

Price target decreased to US$39.25

Recent updates

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth